Clinical trials
COVID-19 trials in the Netherlands
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
98 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2020 | 44 |
| 2021 | 27 |
| 2022 | 19 |
| 2023 | 3 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 56 |
| Unknown status | 19 |
| Terminated | 13 |
| Recruiting | 5 |
| Active, not recruiting | 2 |
| Suspended | 1 |
| Enrolling by invitation | 1 |
| Approved for marketing | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Radboud University Medical Center | 11 |
| University Medical Center Groningen | 11 |
| Erasmus Medical Center | 9 |
| Maastricht University Medical Center | 7 |
| Leiden University Medical Center | 6 |
| UMC Utrecht | 6 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 5 |
| Amsterdam UMC, location VUmc | 3 |
| Gilead Sciences | 3 |
| NEAT ID Foundation | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| COVID-19 | 98 |
| Coronavirus Infections | 7 |
| Severe Acute Respiratory Syndrome | 7 |
| Infections | 6 |
| Pneumonia | 5 |
| Post-Acute COVID-19 Syndrome | 5 |
| Respiratory Distress Syndrome | 4 |
| Disease | 3 |
| Respiratory Tract Infections | 3 |
| Community-Acquired Pneumonia | 2 |
Trials
Showing 26 to 50 of 98. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.